Herbert H. Loong

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

Medicine, Oncology, Metastasis +9

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan et al. · New England Journal of Medicine · 2020 · 836 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers

Vincent Wai‐Sun Wong, Stephen L. Chan, Frankie Mo et al. · Journal of Clinical Oncology · 2010 · 503 citations · Full text

Medicine, Biostatistics, Clinical Epidemiology +16

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 503 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial

Anthony T.�C. Chan, Edwin P. Hui, Roger K.C. Ngan et al. · Journal of Clinical Oncology · 2018 · 245 citations

Medicine, Oncology, Radiation Oncology +17